1. Introduction {#sec1-cancers-12-02313}
===============

Cancer is a major cause of death and therefore a pressing international public health concern \[[@B1-cancers-12-02313],[@B2-cancers-12-02313]\]. Cancer incidence is increasing in all European countries (EC). Sales of cancer drugs have more than doubled between 2005 and 2014 \[[@B3-cancers-12-02313]\]. Because of the recent scientific advances, many new drugs have been developed that can improve overall survival (OS), prolong time to tumor progression (TTP), or decrease the chance of recurrence of cancer \[[@B4-cancers-12-02313]\]. However, access to those drugs is not equal across Europe, as the time from a marketing approval to the actual availability and clinical use of new drugs varies greatly between European Union Member States \[[@B3-cancers-12-02313],[@B5-cancers-12-02313],[@B6-cancers-12-02313]\]. Gann and colleagues observed delays in access to newly registered cancer drugs in some EC of over 4 years \[[@B7-cancers-12-02313]\]. This is worrying as the access to treatment of a disease may affect patient survival, and lack of access conflicts with an individual's right to health \[[@B8-cancers-12-02313]\]. This right was first laid down in the 1946 Constitution of the World Health Organization and in the 1948 Universal Declaration of Human Rights and ever since is an important cornerstone of many health policies \[[@B8-cancers-12-02313]\].

Access to health care has been defined as "the timely use of services according to needs" \[[@B9-cancers-12-02313],[@B10-cancers-12-02313]\]. Novel drugs are faced with long procedures before patients will have access, not only in the developmental phase, but also in the regulatory processes, after finalization of the pivotal trials. The United States (US) and the European Union (EU) each have their own agencies that provide market authorization for new medicines, respectively the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Market authorization is based on the evaluation of safety, efficacy, and quality of the product. Both agencies have special fast track procedures and accelerated approval programs. Moreover, for drugs with high potential patient value, FDA can provide a priority review, that has a maximal review time of 6 months \[[@B11-cancers-12-02313]\]. The accelerated access procedure of EMA should maximally take 150 days, i.e., 5 months \[[@B12-cancers-12-02313]\].

After market authorization, most EC have formal procedures that need to be followed before patients will have access to novel drugs. These procedures commonly include regulatory procedures, price regulations, and some form of health technology assessment to determine whether these drugs will be reimbursed by general means, for instance via a national health services system, or via health insurance schemes \[[@B6-cancers-12-02313],[@B13-cancers-12-02313],[@B14-cancers-12-02313],[@B15-cancers-12-02313],[@B16-cancers-12-02313]\]. Given the increasing pressure on health care budgets, these national procedures are becoming increasingly complex. The procedures and the time they take differ substantially across countries.

Although it is in society's interest that new drugs, which are proven beneficial to patients, are equally accessible for people in need, it seems to be more and more difficult for EC to strike a balance between benefits and costs of novel cancer drugs \[[@B17-cancers-12-02313],[@B18-cancers-12-02313]\]. As countries cope differently, resulting in variations in patient access, a deeper insight into the problem and its anticipated consequences is necessary.

The aim of this study is to assess variations in national patient access to several newly registered cancer drugs across Europe. Therefore, we compared the dates of submissions to FDA and EMA, the time to first uptake, and speed of uptake of these drugs and explored the impact of observed variations in access in terms of health outcomes.

2. Methods {#sec2-cancers-12-02313}
==========

This was a retrospective database study. Data were obtained from the following sources: pharmaceutical sales data was obtained from IQVIA's MIDAS^®^ database \[[@B19-cancers-12-02313]\]. Sales recorded in MIDAS can originate from both retail or hospital setting. The coverage differs by country and setting. Sales were expressed in standard units (SU)---defined as single tablet or vial---making it impossible to differentiate between dosages. We assumed the usage of varying dosages are similar across included countries. IQVIA's MIDAS^®^ database did not encompass data on selected drugs for the Netherlands. Dutch data on first uptake were available for all drugs. However, sales data were obtained from manufactures (*n* = 8). We assumed sales data give a good approximation for the usage and access to selected drugs, as it is unlikely that influence of potential stocking of inventories is minimal.

We selected a variety of newly registered cancer drugs. The selection of the drugs was based on diversity in clinical evidence and diversity among indications. We limited our analysis to 12 "end of life medicines" for the indications breast cancer, gastric cancer, prostate cancer, and melanoma. The selected drugs are listed in [Table 1](#cancers-12-02313-t001){ref-type="table"}. They were first registered between 2011 and 2017 and clinical evidence levels, as determined by the European Society Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) \[[@B20-cancers-12-02313]\], differed. This scale considers outcomes such as (progression-free) survival and drug toxicity. It was hypothesized that the time to patient access may be shorter for drugs with high clinical benefit score (e.g., ESMO-MCBS score 4 or 5) than for drugs with a lower clinical benefit score (e.g., ESMO-MCBS score 2 or 3). Abiraterone, cabazitaxel, vemurafenib, enzalutamide, Palbociclib, and ribociclib had a priority review by FDA. Abiraterone, vemurafenib, and nivolumab underwent a fast track procedure at EMA.

General and indication-specific cancer data were used for determining the mortality rates per drug indication. Specific cancer mortality data were obtained from Eurostat for the years 2011--2015, mortality for the missing years 2016--2018 was based on extrapolations \[[@B21-cancers-12-02313]\]. Analyses are performed on data from 2010--2018, for 28 European countries ([Appendix A](#app1-cancers-12-02313){ref-type="app"}).

Subsequently, the time to patient access was determined for each drug. Time to patient access was defined as the sum of: (i) Time from regulatory submission to regulatory approval; (ii) time to first patient access, i.e., time to market (TTM); and (iii) speed of uptake of the drug ([Figure 1](#cancers-12-02313-f001){ref-type="fig"}).

The "time to market" for 28 European countries was calculated from the date of EMA registration of the drug to the dates of first sales in each country ([Figure 1](#cancers-12-02313-f001){ref-type="fig"}). These dates were defined as dates of first uptake and were obtained from IQVIA's MIDAS^®^ database \[[@B19-cancers-12-02313]\]. The speed of uptake was calculated by aggregating sales data (in standard units (SU) into the first 24 months of availability in a country and dividing by country-and indication-specific mortality, expressed by the number of cancer (specific) deaths as all drugs were registered for end of life settings. In the case of medicines with multiple indications, data were related to the overall cancer mortality in a country. As in general not all patients are in the appropriate medical condition to receive a new drug, we hypothesized that 80% of the eligible patients should have had access to the drugs.

Thereafter, time to first patient access in the 28 European countries was calculated. For the time of first patient access the date of EMA registration and first uptake in a country were calculated for each drug separately. As sales data are being reported on monthly basis, we assumed that the first uptake date would always be on the 1st of every month. Thereafter, these number of days were averaged for all 12 drugs.

Additionally, the speed of uptake in a country has been calculated by using the following formula:$$Speed~of~uptake~drug~in~country = \sum\limits_{n = 1}^{n = 12}\left( \frac{sales~volume~drug~after~1~and~2~years}{mortality~of~drug~indication~in~these~years} \right)$$ *n* = type of drug, 12 drugs included in the analysis.

The sales volumes were calculated by summing up the sales volumes after exactly 1 and 2 years after the date of first uptake per drug per country. The outcomes were divided by the mortality that corresponded to the drug indication and the year. Thereof the average rank of all studied drugs per country has been derived.

To illustrate the impact of delay in patient access in European countries, we selected ipilimumab and abiraterone, as these drugs have a high clinical value (ESMO 4) and the trial results have shown an impact on the overall survival, namely an increase by 3.7 months and 3.9 months, respectively \[[@B22-cancers-12-02313],[@B23-cancers-12-02313]\]. We calculated the loss in life years (LYs) due to a delayed access in their first year after market approval as for both drug indications new comparators were introduced later in time. We also estimated the loss in LYs due to a later introduction in Europe as compared to the US. For the number of patients in need for abiraterone and ipilimumab we used the dosing and the median number of cycles from the clinical trials \[[@B23-cancers-12-02313],[@B24-cancers-12-02313]\]. The latter was related to the time to disease progression.

Further, the relation between FDA or EMA and between the ESMO-MCBS on the time to market and the speed of uptake has been studied by means of regression analyses (ANOVA). The ESMO-MCBS score was based on the results of the first publication. All statistical analyses were performed in SPSS Statistics version 25 for Windows (SPSS Inc. Chicago, IL, USA).

3. Results {#sec3-cancers-12-02313}
==========

[Table 1](#cancers-12-02313-t001){ref-type="table"} and [Appendix A](#app1-cancers-12-02313){ref-type="app"} show the dates of the submission to, and approval by the EMA and FDA. The dates of submission to EMA and FDA were almost comparable, with the exception of palbociclib (395 days later in Europe). All drugs were first approved in the US. On average, the time to first registration was 181 days in the US (range 78--303 days) vs. 378 days in Europe (range 262--483 days), implying a difference in duration of the procedures of 197 days. Marketing approval for the cancer drugs came on average 242 days later in Europe than in the US. For the three drugs assessed in the accelerated trajectory of EMA, the average assessment period was 280 days. For drugs in the standard trajectory, this period was 410 days. The 6 drugs undergoing priority review by FDA, took an average time to market approval of 139 days, compared to 223 days for the drugs in the regular trajectory.

In [Figure 2](#cancers-12-02313-f002){ref-type="fig"}, the EMA trajectory is presented per studied drug. The actual EMA assessment time averaged 204 days and the time the applicants needed to answer queries averaged 86 days. The time between submission of the dossier and the start of the regulatory assessment procedure averaged 27 days, while the time between a positive opinion and approval averaged 61 days.

Further, there was no relation found in time between registration by FDA or EMA, and clinical value of the drugs as defined by clinical outcomes (OS, PFS, or TTP), or ESMO-MCBS score. For example, ipilimumab resulted in a gain of 3.7 months in OS and had an ESMO-MCBS score 4 and it took EMA 433 days to approve (FDA: 278 days). In contrast, for cabazitaxel, with 2.4 months increase in time to progression and ESMO-MCBS score 2 market authorization was given 331 days after submission of the EMA dossier (FDA priority review: 78 days).

[Figure 3](#cancers-12-02313-f003){ref-type="fig"} and [Appendix B](#app2-cancers-12-02313){ref-type="app"} present the average time from EMA registration to first uptake of the studied drugs across Europe. 2--8 Years after marketing approval, several countries still either had a very low uptake of drugs, or no uptake at all. Palbociclib had the fastest time to market from EMA registration until first uptake in the EC (average: 165 days), followed by nivolumab (average: 210 days), but 2 years after European market approval, these drugs were still not prescribed to patients in four and five countries, respectively. Note that, despite the relatively fast uptake of palbociclib, the time between US and EU market access was almost two years. For nivolumab this period was shorter, namely 179 days.

The average TTM in Europe amounted to 398 days (range 17--1187 days). In general, patients in Germany, the UK, and Austria had the most rapid potential access, with averages of 17, 22, and 31 days, respectively. Greece and many Eastern European countries were below the European average.

[Figure 4](#cancers-12-02313-f004){ref-type="fig"} shows the speed of uptake of drugs 2 years after approval in a country. Belgium, Switzerland, France, and Austria had the highest uptake after two years. The UK and Sweden had relatively slow uptakes after 2 years.

Concerning the time to first uptake in Eastern EC, Poland was fastest, followed by Slovakia and Slovenia. First patient access to the drugs in these countries was faster than, for instance, Spain, Ireland and Italy. Bulgaria, Romania, Croatia, and Latvia ranked low in time to first access, but both Bulgaria and Czech Republic thereafter had a rapid uptake.

A delay in patient access to new drugs may result in diminished patient benefits. We calculated that in Europe approximately 14,994 patients were eligible for treatment with ipilimumab in the first year after EMA approval (see [Table 2](#cancers-12-02313-t002){ref-type="table"} and [Appendix C](#app3-cancers-12-02313){ref-type="app"}). Taking into account the sales per country in that first year approximately 11,184 melanoma patients were not treated with ipilimumab. Assuming an average gain in OS of 3.7 months (derived from [Table 1](#cancers-12-02313-t001){ref-type="table"}), this may have resulted in a loss of 3448 life years. Applying the same calculation to prostate cancer patients eligible for abiraterone resulted in 55,853 non-treated patients, which would indicate a loss of 18,152 life years across Europe for abiraterone non-use. The delay in the EMA time to registration compared to the FDA time led to an extra estimated loss of 8639 life years for both drugs.

4. Discussion {#sec4-cancers-12-02313}
=============

The results of our study show that, although the dates of submission to EMA and FDA did not differ for most drugs, on average newly registered cancer drugs entered the European market eight months later than the USA market. Moreover, time to patient access to the 12 newly registered cancer drugs included in the analyses differed strongly across Europe. Our analysis is the first showing the potential impact of a delay in access for patients. In the first year after EMA market authorization of ipilimumab and abiraterone almost 67,000 patients were unable to benefit from these drugs, resulting in an estimated loss of 21,600 life years. The longer EMA time to registration, as compared to the FDA time to registration, led to an extra estimated loss of 8693 life years.

Wilking and Jonsson previously studied patients' access to treatments in the five most common tumor types for the period 1999--2004 \[[@B5-cancers-12-02313]\]. In that period Austria, Spain, and Switzerland were fastest in realizing patient access. As in our study the UK was quite slow in adoption of the cancer treatments. Another study compared the uptake and market share for direct acting antivirals in six European countries \[[@B25-cancers-12-02313]\]. In Germany and France patients had early access and these countries were fast adopters of these drugs. Spain and Italy were late in first uptake, but they were fast adopters after first uptake. In the UK, patients had fast access, but the uptake was slow.

As all European countries cope differently with newly registered drugs, resulting in variation in patient access, a deeper understanding of the facilitators, barriers, and key actors involved in this process is necessary. According to Frost and Reich, access to an innovation depends of several factors, such as availability, affordability, and adoption of the intervention \[[@B26-cancers-12-02313]\]. The availability of a newly registered drug in a country will be influenced by factors like time of market authorization, the duration of the reimbursement procedure and health technology assessment, the used pricing system (e.g., external reference pricing (ERP)) and the value of the drug. Affordability means that the drug is not too expensive. This is mainly influenced by the price, the gross domestic product (GDP) of a country, the health care expenditure of a country, the pharmaceutical spending of country, and the financing (co-payments or limits on number of patients treated). Adoption depends on the acceptance and amount of unmet need of the intervention as perceived by several actors, such as global organizations (FDA or EMA), governments, doctors, and individual patients. Further study of the facilitators, barriers, and key actors involved in the access of new drugs are highly recommended.

Recently, several methods have been developed in Europe and the US to deal with the assessment of the value and pricing of newly registered drugs, and their affordability in the health systems. Examples are the American Society for Clinical Oncology (ASCO) Value in Cancer Care Framework and the ESMO-MCBS \[[@B18-cancers-12-02313],[@B27-cancers-12-02313]\]. These methods focus on the clinical benefit of the drugs and (partly) on value-based pricing, addressing cost or cost-effectiveness of the new drug. In this study we have used the ESMO-MCBS to assess the clinical value of the studied drugs, but other instruments could be used as well. We expected that higher values of the ESMO-MCBS would result in a faster access. However, in our study a higher value, i.e., ESMO-MCBS 4--5, did not lead to a faster access of patients to these drugs.

Our study has a number of limitations. First, this study was based on data from several retrospective data sources. Each data source has several strong and weak points. IQVIA's MIDAS^®^ database includes worldwide standardized sales data allowing unique cross-country comparisons over time. However, in some countries not all distribution channels (e.g., hospital/retail) are captured and the database does not include direct sales to clinics and private offices in all countries. Moreover, data coverage differs per country, which despite regular quality and validity checks, potentially impacts accuracy of data extrapolations.

Second, there may be differences in the quality of the registrations of cancer mortality in the EC. Some countries may have more reliable data than other countries. However, the methods to calculate the mortality rates are standardized.

Third, some drugs had registrations for the same indication or for a specific sub-indication (e.g., melanoma for patients with PDL-1 expression) and could be used as substitutes. Further, some drugs are used for multiple indications (e.g., nivolumab: lung cancer, melanoma). In case of multiple indications, we used overall cancer mortality rates of the countries to compare the uptake. As a result, we could not calculate the exact loss in life years as a result of the delay in access of patients to these treatments. Loss in palliative effect of the drugs (i.e., lost potential effects on quality of life rather than survival) is something we could also not assess.

Fourth, data about uptake of drugs should ideally be collected by using registry data, capturing data on patient and disease characteristics, and real-world use of the drugs (dosing and number of days/cycles). In the absence of such data in Europe, we used data from IQVIA MIDAS, Eurostat, and clinical trials \[[@B19-cancers-12-02313],[@B21-cancers-12-02313],[@B22-cancers-12-02313],[@B23-cancers-12-02313]\]. Data on speed of uptake were based on sales data and on country specific cancer mortality rates as the drugs were end of life products. We estimated that 80% of the patients in real life were eligible for the drugs, as some patients would be too unfit and/or would have too many co-morbidities to enable treatment. For the number of patients in need for abiraterone and ipilimumab we used data from the clinical trials. It is possible that in clinical practice patients may receive fewer cycles, implying that more patients may have received these drugs. If so, this has resulted in a slight overestimation of loss of life years.

Fifth, the inclusion of drugs was based on a pragmatic approach. A different selection of drugs may have resulted in different time to access estimated. Moreover, this study was focused on patient access to oncology drugs. Time to access and uptake may be different in other disease areas.

Finally, we selected two drugs to give an illustration of life years lost in Europe due to delays in patient access. The estimation of life years lost is based on a high-level calculation. It would be worthwhile to conduct a study including more drugs and more elaborate calculations.

Time to patient access in Europe is influenced by the complexity of national reimbursement processes. Most pharmaceutical companies first launch their product in Germany as it is the largest European market and reimbursement is automatic once EMA has approved drugs. A year of free pricing is allowed while price and reimbursement negotiations are ongoing \[[@B28-cancers-12-02313]\]. Countries in which the reimbursement is dependent on the outcome of cost-effectiveness assessments (e.g., UK and The Netherlands) or in which lengthy negotiations with national and regional decision-makers have to take place (e.g., Spain and Italy) take a longer time to first access and have more limited uptake after two years. We assumed market access to be similar in all countries because of the centralized EMA procedure, however Norway and Switzerland have their own agencies, resulting in a 75-and 66-day delay, respectively \[[@B29-cancers-12-02313],[@B30-cancers-12-02313]\]. Therefore, time to patient access in Norway and Switzerland has been slightly overestimated.

Several aspects can help shortening the time to patient access and increase uptake.

Specific early access programs can help facilitate early launches as exemplified in France, Sweden, and Italy \[[@B27-cancers-12-02313]\]. Since the current processes of early access programs are generally complex, governments may be able to better facilitate these programs, for instance by allowing pharmaceutical companies to provide the medicines for free during the process of price negotiations and to reimburse the drugs according to the negotiated price once the negotiations have ended. The FDA assessment was on average substantially faster than the EMA assessment. This was during the whole study period (2010--2018). Therefore, improvements in the EMA procedure seem possible \[[@B31-cancers-12-02313]\]. For instance, shortening the time from EMA submission to procedure start and the time from positive opinion to approval may accelerate the process by almost 3 months.

The coming decade, the number of patients with cancer is estimated to increase by 68% \[[@B32-cancers-12-02313]\]. As stated before, patients have a right to health, i.e., the highest attainable standard of health as a fundamental right of every human being \[[@B8-cancers-12-02313]\]. This makes it a legal obligation of countries to ensure timely access to acceptable and affordable health care of appropriate quality \[[@B32-cancers-12-02313]\]. Fortunately, this issue will be addressed in the Pharmaceutical Strategy for Europe commissioned by the European Commission \[[@B33-cancers-12-02313]\]. As many novel cancer drugs have entered the market and many others are upcoming, it is of utmost importance that all patients in need get access to the drugs with high clinical value as soon as possible.

5. Conclusions {#sec5-cancers-12-02313}
==============

This study shows that it takes a long time for European patients to get access to newly registered cancer drugs. Further, there is great inter-country variation of access to new cancer drugs. The delay in access may result in a potential loss of many life years. The health outcomes of European patients can substantially be improved by enabling faster and more general use of available new medicines.
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###### 

Time from drug submission to drug approval by EMA (A) and FDA (B).

cancers-12-02313-t0A1a_Table A1

###### 

(**A**)

  Drug                                           Date of EMA Submission   Start Procedure     Rapporteur's First Assessment Report   List of Question to the Applicant   Answers from the Applicant   Outstanding Issues   Response to Outstanding Issues   CHMP Positive Opinion   Approval           Accelerated Assessment (EMA)   Total EMA (in Days)
  ---------------------------------------------- ------------------------ ------------------- -------------------------------------- ----------------------------------- ---------------------------- -------------------- -------------------------------- ----------------------- ------------------ ------------------------------ ---------------------
  Abiraterone                                    17 December 2010         19 January 2011     11 April 2011                          20 May 2011                         17 June 2011                 n.a.                 n.a.                             21 July 2011            5 September 2011   16 December 2010               262
  Cabazitaxel                                    20 April 2010            26 May 2010         12 August 2010                         24 September 2010                   15 October 2010              n.a.                 n.a.                             20 January 2011         17 March 2011      n.a.                           331
  Dabrafenib                                     24 July 2012             15 August 2012      5 November 2012                        14 December 2012                    21 February 2013             25 April 2013        23 May 2013                      27 June 2013            26 August 2013     n.a.                           398
  Ipilimumab                                     5 May 2010               26 May 2010         15 August 2010                         24 September 2010                   12 January 2011              17 Mar 2011          18 April 2011                    19 May 2011             12 July 2011       n.a.                           433
  Nivolumab                                      2 September 2014         24 September 2014   15 December 2014                       22 January 2015                     20 February 2015             26 March 2015        30 March 2015                    23 April 2015           19 June 2015       24 July 2014                   290
  Vemurafenib                                    4 May 2011               25 May 2011         12 August 2011                         22 September 2011                   14 October 2011              17 November 2011     24 November 2011                 15 December 2011        17 February 2012   14 April 2011                  289
  Pertuzumab                                     1 December 2011          21 December 2011    14 March 2012                          20 April 2012                       17 August 2012               18 October 2012      12 November 2012                 13 December 2012        4 March 2013       n.a.                           459
  Enzalutamide                                   26 June 2012             15 August 2012      2 November 2012                        14 December 2012                    16 January2013               21 March 2013        25 March 2013                    25 April 2013           21 June 2013       n.a.                           360
  Pembrolizumab                                  4 June 2014              25 June 2014        12 September 2014                      24 October 2014                     20 February 2015             23 April 2015        27 April 2015                    21 May 2015             17 July 2015       n.a.                           408
  Ramucirumab                                    23 August 2013           25 September 2013   12 December 2013                       23 January2014                      24 April 2014                26 June 2014         14 August 2014                   25 September 2014       19 December 2014   n.a.                           483
  Palbociclib                                    30 July 2015             20 August 2015      9 November 2015                        17 December 2015                    22 April 2016                23 June 2016         15 August 2016                   15 September 2016       9 November 2016    n.a.                           468
  Ribociclib                                     5 September 2016         29 September 2016   20 December 2016                       26 January2017                      17 February 2017             21 April 2017        22 May 2017                      22 June 2017            22 August 2017     n.a.                           351
  Average time from submission to approval EMA                                                                                                                                                                                                                                      378                                               
  Average time accelerated assessment EMA                                                                                                                                                                                                                                           280                                               
  Average time no accelerated assessment EMA                                                                                                                                                                                                                                        410                                               

EMA: European Medicines Agency; CHMP: Committee for Medicinal Products for Human Use.

cancers-12-02313-t0A1b_Table A1

###### 

(**B**)

                                                 Date of FDA Submission   Date of FDA Approval   Priority Review (FDA)   Total Time FDA (in Days)
  ---------------------------------------------- ------------------------ ---------------------- ----------------------- --------------------------
  Abiraterone                                    20 December 2010         28 April 2011          Yes                     129
  Cabazitaxel                                    31 March 2010            17 June 2010           Yes                     78
  Dabrafenib                                     30 July 2012             29 May 2013            No                      303
  Ipilimumab                                     10 June 2010             15 March 2011          No                      278
  Nivolumab                                      30 July 2014             22 December 2014       No                      145
  Vemurafenib                                    28 April 2011            17 August 2011         Yes                     111
  Pertuzumab                                     6 December 2011          8 June 2012            No                      185
  Enzalutamide                                   22 May 2012              31 August 2012         Yes                     101
  Pembrolizumab                                  27 February 2014         3 September 2014       No                      188
  Ramucirumab                                    23 August 2013           21 April 2014          No                      241
  Palbociclib                                    30 June 2014             3 February 2015        Yes                     218
  Ribociclib                                     29 August 2016           13 March 2017          Yes                     196
  Average time from submission to approval FDA                            181                                            
  Average time priority review FDA                                                               139                     
  Average time no priority review FDA                                     223                                            

FDA: USA Food and Drug Association.

cancers-12-02313-t0A2_Table A2

###### 

Time from EMA registration until first uptake per drug per country (in days).

       Country            Abirate-Rone   Cabazi-Taxel   Dabra-Fenib   Ipili-Mumab   Nivolu-Mab   Vemura-Fenib   Pertuzu-Mab   Enzalu-Tamide   Pembroli-Mumab   Ramuci-Mumab   Palboci-Clib   Riboci-Clib   Average   No Access \*
  ---- ------------------ -------------- -------------- ------------- ------------- ------------ -------------- ------------- --------------- ---------------- -------------- -------------- ------------- --------- --------------
  1    Germany            26             0              36            0             12           13             28            0               72               11             0              10            17        0
  2    UK                 0              15             97            19            12           13             0             0               41               0              0              71            22        0
  3    Austria            0              0              67            50            12           13             58            0               72               11             22             71            31        0
  4    Sweden             0              0              36            19            12           13             0             26              41               192            0              101           37        0
  5    France             0              168            67            0             0            258            272           0               103              39             0                            82        1
  6    Finland            331            0              67            172           12           13             0             87              72               70             173                          91        1
  7    Switzerland        26             15             159           80            165          0              0             87              103              314            84             101           95        0
  8    Norway             57             0              128           385           74           135            211           26              133              100            0              163           118       0
  9    Netherlands \*\*   176            247            53            197           20           135            140           12              116              40             234            163           128       0
  10   Portugal           0              0              918           232           43           470            303           57              0                376            84             0             207       0
  11   Poland             149            76             674           203           74           166            119           149             407              405            143            222           232       0
  12   Slovakia           149            76             67            538           470          0              303           634             72               253            112                          243       1
  13   Slovenia           270            381            371           172           652          258            423           299             0                436            0              191           288       0
  14   Spain              118            76             279           446           196          623            454           452             225              314            357            101           303       0
  15   Ireland            149            685            371           172           74           378            89            391             377              131            538                          305       1
  16   Italy              543            229            432           597           104          470            150           177             194              253            143            405           308       0
  17   Hungary            362            1690           340           446           43           13             119           299             256              131            84             375           347       0
  18   Belgium            300            350            248           293           256          378            454           422             377              892            387            343           392       0
  19   Czech              392                           1283                        621          409            454           118             225              131            143                          420       3
  20   Bulgaria           788            838            949                         562          288            393           483             256              376            265                          520       2
  21   Romania            757            1203           674           111           378          105            242           1214            742                             296                          572       2
  22   Croatia            1426           1568           736                         348          197            454           695             346              862            387            343           669       1
  23   Latvia             1334                                                                   1200                                         285                             173                          748       8
  24   Lithuania          1061           1384           797           1633                       500            819                           591              405            326                          835       3
  25   Servia             969            2115           1283                                     684            576           969             499                                                          1014      5
  26   Greece                                                                                    1018                         1548                                                           405           990       9
  27   Bosnia                                           1558                                     743            546           1610            925                                                          1076      7
  28   Estonia            1122           2056           889                         682                                                                                                                    1187      8
       Average            404            549            484           288           210          315            264           390             251              261            165            192           403       1.9

\* Number of countries with no access; \*\* Data missing for cabazitaxel, enzalutamide, palbociclib, dabrafenib; EMA: European Medicines Agency.

###### 

Calculation of number of lost life years ipilimumab (A) and abiraterone (B).

cancers-12-02313-t0A3a_Table A1

###### 

(**A**)

  A                Number of Melanoma Deaths in 2012 \*   Number of Patients Need Ipilimumab (80%)   Perc. Patients not Treated 1 Year after EMA approval   Number of Patients Not Treated   Number of Lost Life Years after EMA Approval   Number of Lost Life Years between FDA-EMA Approval \*\*   Total Number of Lost Life Years due to Delay
  ---------------- -------------------------------------- ------------------------------------------ ------------------------------------------------------ -------------------------------- ---------------------------------------------- --------------------------------------------------------- ----------------------------------------------
  Austria          385                                    308                                        53%                                                    163                              50                                             31                                                        81
  Belgium          315                                    252                                        89%                                                    225                              69                                             26                                                        95
  Bulgaria         161                                    129                                        100%                                                   129                              40                                             13                                                        53
  Croatia          188                                    150                                        100%                                                   150                              46                                             15                                                        62
  Czech Republic   463                                    370                                        100%                                                   370                              114                                            38                                                        152
  Estonia          55                                     44                                         100%                                                   44                               14                                             4                                                         18
  Finland          222                                    178                                        92%                                                    164                              50                                             18                                                        68
  France           1853                                   1482                                       41%                                                    601                              185                                            150                                                       336
  Germany          2705                                   2164                                       59%                                                    1278                             394                                            219                                                       613
  Hungary          407                                    325                                        100%                                                   325                              100                                            33                                                        133
  Ireland          216                                    173                                        83%                                                    143                              44                                             17                                                        61
  Italy            1757                                   1406                                       100%                                                   1406                             433                                            143                                                       576
  Latvia           77                                     61                                         100%                                                   61                               19                                             6                                                         25
  Lithuania        104                                    83                                         100%                                                   83                               26                                             8                                                         34
  Netherlands      887                                    710                                        89%                                                    629                              194                                            72                                                        266
  Norway           383                                    306                                        100%                                                   306                              94                                             31                                                        125
  Poland           1564                                   1251                                       100%                                                   1248                             385                                            127                                                       512
  Portugal         259                                    207                                        98%                                                    204                              63                                             21                                                        84
  Romania          443                                    354                                        41%                                                    146                              45                                             36                                                        81
  Serbia           276                                    221                                        100%                                                   221                              68                                             22                                                        90
  Slovakia         236                                    189                                        100%                                                   189                              58                                             19                                                        77
  Slovenia         130                                    104                                        99%                                                    103                              32                                             11                                                        42
  Spain            971                                    777                                        100%                                                   777                              240                                            79                                                        318
  Sweden           569                                    455                                        94%                                                    429                              132                                            46                                                        178
  Switzerland      399                                    319                                        58%                                                    184                              57                                             32                                                        89
  United Kingdom   2466                                   1973                                       81%                                                    1606                             495                                            200                                                       695
  Total/Average    17,492                                 13,993                                     88%                                                    11,184                           3448                                           1418                                                      4867

Source: reference 19; \* Time between FDA and EMA approval of abiraterone: 130 days; Perc: percentage; EMA: European Medicines Agency; FDA: USA Food and Drug Association.

cancers-12-02313-t0A3b_Table A1

###### 

(**B**)

  B                Number of Prostate Cancer Deaths in 2012 \*   Number of Patients Need Abiraterone (80%)   Perc. Patients not Treated 1 Year after EMA Approval   Number of Patients Not Treated   Number of Lost Life Years after EMA Approval   Number of Lost Life Years between FDA-EMA Approval \*\*   Total Number of Lost Life Years due to Delay
  ---------------- --------------------------------------------- ------------------------------------------- ------------------------------------------------------ -------------------------------- ---------------------------------------------- --------------------------------------------------------- ----------------------------------------------
  Austria          1238                                          990                                         63%                                                    626                              204                                            115                                                       318
  Belgium          1513                                          1210                                        96%                                                    1157                             376                                            140                                                       516
  Bulgaria         959                                           767                                         100%                                                   767                              249                                            89                                                        338
  Croatia          780                                           624                                         100%                                                   624                              203                                            72                                                        275
  Czech Republic   1693                                          1354                                        100%                                                   1354                             440                                            157                                                       597
  Estonia          268                                           215                                         100%                                                   215                              70                                             25                                                        95
  Finland          914                                           731                                         99%                                                    721                              234                                            85                                                        319
  France           9217                                          7374                                        75%                                                    5549                             1803                                           854                                                       2657
  Germany          12,158                                        9726                                        78%                                                    7588                             2466                                           1126                                                      3592
  Hungary          1285                                          1028                                        100%                                                   1028                             334                                            119                                                       453
  Ireland          903                                           723                                         100%                                                   721                              234                                            84                                                        318
  Italy            6502                                          5202                                        100%                                                   5202                             1691                                           602                                                       2293
  Latvia           400                                           320                                         100%                                                   320                              104                                            37                                                        141
  Lithuania        598                                           478                                         100%                                                   478                              155                                            55                                                        211
  Netherlands      3154                                          2523                                        89%                                                    2254                             733                                            292                                                       1025
  Norway           1263                                          1010                                        83%                                                    839                              273                                            117                                                       390
  Poland           5475                                          4380                                        99%                                                    4358                             1416                                           507                                                       1923
  Portugal         1776                                          1421                                        99%                                                    1404                             456                                            164                                                       621
  Romania          2432                                          1945                                        100%                                                   1945                             632                                            225                                                       857
  Serbia           1104                                          883                                         100%                                                   883                              287                                            102                                                       389
  Slovakia         997                                           798                                         99%                                                    789                              256                                            92                                                        349
  Slovenia         445                                           356                                         98%                                                    349                              113                                            41                                                        155
  Spain            6266                                          5012                                        95%                                                    4755                             1545                                           580                                                       2126
  Sweden           2532                                          2026                                        89%                                                    1795                             583                                            235                                                       818
  Switzerland      1465                                          1172                                        80%                                                    938                              305                                            136                                                       440
  United Kingdom   12,639                                        10,111                                      91%                                                    9195                             2988                                           1170                                                      4159
  Total/Average    77,975                                        62,380                                      94%                                                    55,853                           18,152                                         7221                                                      25,373

Source: reference 19; \* Time between FDA and EMA approval of abiraterone: 130 days; Perc: percentage; EMA: European Medicines Agency; FDA: USA Food and Drug Association.

![Patient newly registered drug access pathway. EMA: European Medicines Agency; FDA: USA Food and Drug Association; HTA: health technology assessment; TTM: time to market.](cancers-12-02313-g001){#cancers-12-02313-f001}

![EMA trajectory of 12 newly registered oncological drugs (in days). EMA: European Medicines Agency.](cancers-12-02313-g002){#cancers-12-02313-f002}

![Time to first uptake for 12 newly registered oncological drugs across Europe (in days).](cancers-12-02313-g003){#cancers-12-02313-f003}

![Speed of drug uptake for 12 newly registered oncological drugs in first two years across Europe (average rank, range) (Note: Too little access data for ranking: Lithuania, Greece, Bosnia, Estonia).](cancers-12-02313-g004){#cancers-12-02313-f004}

cancers-12-02313-t001_Table 1

###### 

Newly registered oncological drugs, first indications, clinical values, and duration of EMA and FDA procedures.

  Drug                                                                          First Indication   Gain PFS, OS, TTP (Median, Months)   ESMO-MCBS \*   Date of EMA Submission   Date of EMA Approval   Accelerated Assessment (EMA)   Total Time EMA (in Days)   Date of FDA Submission   Date of FDA Approval   Priority Review (FDA)   Total Time FDA (in Days)   Time between EMA and FDA Approval (in Days)
  ----------------------------------------------------------------------------- ------------------ ------------------------------------ -------------- ------------------------ ---------------------- ------------------------------ -------------------------- ------------------------ ---------------------- ----------------------- -------------------------- ---------------------------------------------
  Abiraterone                                                                   Prostate cancer    3.9 months OS                        4              17 December 2010         5 September 2011       16 December 2010               262                        20 December 2010         28 April 2011          Yes                     129                        130
  Cabazitaxel                                                                   Prostate cancer    2.4 months TTP                       2              20 April 2010            17 March 2011          n.a.                           331                        31 March 2010            17 June 2010           Yes                     78                         273
  Dabrafenib                                                                    Melanoma           2.4 months PFS                       4              24 July 2012             26 August 2013         n.a.                           398                        30 July 2012             29 May 2013            No                      303                        89
  Ipilimumab                                                                    Melanoma           3.7 months OS                        4              05 May 2010              12 July 2011           n.a.                           433                        10 June 2010             15 March 2011          No                      278                        119
  Nivolumab                                                                     Melanoma           4.0 months PFS                       4              02 September 2014        19 June 2015           24 July 2014                   290                        30 July 2014             22 December 2014       No                      145                        179
  Vemurafenib                                                                   Melanoma           3.7 months PFS                       4              04 May 2011              17 February 2012       14 April 2011                  289                        28 April 2011            17 August 2011         Yes                     111                        184
  Pertuzumab                                                                    Breast cancer      6.1 months PFS                       4              01 December 2011         4 March 2013           n.a.                           459                        06 December 2011         08 June 2012           No                      185                        269
  Enzalutamide                                                                  Prostate cancer    4.8 months OS                        4              26 June 2012             21 June 2013           n.a.                           360                        22 May 2012              31 August 2012         Yes                     101                        294
  Pembrolizumab                                                                 Melanoma           1.3 months PFS                       3              04 June 2014             17 July 2015           n.a.                           408                        27 February 2014         03 September 2014      No                      188                        317
  Ramucirumab                                                                   Gastric cancer     2.2 months OS                        2              23 August 2013           19 December 2014       n.a.                           483                        23 August 2013           21 April 2014          No                      241                        242
  Palbociclib                                                                   Breast cancer      10.3 months PFS                      3              30 July 2015             9 November 2016        n.a.                           468                        30 June 2014             03 February 2015       Yes                     218                        645
  Ribociclib                                                                    Breast cancer      PFS not reached                      3              05 September 2016        22 August 2017         n.a.                           351                        29 August 2016           13 March 2017          Yes                     196                        162
  Average time (in days)                                                                                                                                                        378                                                                                                       181                    242                                                
  Average time accelerated assessment/priority review (in days)                                                                                        280                                                                                                       139                      n.a.                                                                      
  Average time in case no accelerated assessment/no priority review (in days)                                                           410                                                                                           223                        n.a.                                                                                               

\* Ref. \[[@B22-cancers-12-02313]\] PFS: progression-free survival; OS: overall survival; TTP: time to progression, ESMO-MCBS: European Society Medical Oncology-Magnitude of Clinical Benefit Scale; EMA: European Medicines Agency; FDA: USA Food and Drug Association; n.a.: not applicable.
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###### 

Potential life years lost due to delay in access in abiraterone and ipilimumab across Europe.

  Country                 Abiraterone   Ipilimumab                          
  ----------------------- ------------- ------------ -------- ------ ------ ------
  Austria                 115           204          318      31     50     81
  Belgium                 140           376          516      26     69     95
  Bulgaria                89            249          338      13     40     53
  Croatia                 72            203          275      15     46     62
  Czech Republic          157           440          597      38     114    152
  Estonia                 25            70           95       4      14     18
  Finland                 85            234          319      18     50     68
  France                  854           1803         2657     150    185    336
  Germany                 1126          2466         3592     219    394    613
  Hungary                 119           334          453      33     100    133
  Ireland                 84            234          318      17     44     61
  Italy                   602           1691         2293     143    433    576
  Latvia                  37            104          141      6      19     25
  Lithuania               55            155          211      8      26     34
  Netherlands             292           733          1025     72     194    266
  Norway                  117           273          390      31     94     125
  Poland                  507           1416         1923     127    385    512
  Portugal                164           456          621      21     63     84
  Romania                 225           632          857      36     45     81
  Serbia                  102           287          389      22     68     90
  Slovakia                92            256          349      19     58     77
  Slovenia                41            113          155      11     32     42
  Spain                   580           1545         2126     79     240    318
  Sweden                  235           583          818      46     132    178
  Switzerland             136           305          440      32     57     89
  United Kingdom          1170          2988         4159     200    495    695
  Total life years lost   7221          18,152       25,373   1418   3448   4867
